Patents Examined by Kamal Saeed
  • Prodigiosin analogs and methods of use
    Patent number: 11535608
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: December 27, 2022
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Amide compounds and method for making and using
    Patent number: 11530194
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: December 20, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
  • Tetrazole azasydnone
    Patent number: 11530203
    Abstract: The present disclosure relates to a novel tetrazole azasydnone, a method of making the novel tetrazole azasydnone, and a method of using the novel tetrazole azasydnone as a primary explosive. In one aspect, the novel tetrazole azasydnone has a structure of formula I: wherein A? represents a cation with a 1+ charge.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: December 20, 2022
    Assignee: Purdue Research Foundation
    Inventors: Davin Glenn Piercey, Matthew Lee Gettings
  • Nickel-based metal-organic framework as catalyst for chemical fixation of COin oxazolidinone synthesis
    Patent number: 11529621
    Abstract: A method of fixating CO2 to form a substituted oxazolidinone is described. The method includes mixing a nickel-based metal-organic framework (Ni-MOF) catalyst of formula [Ni3(BTC)2(H2O)3]·(DMF)3(H2O)3, a cocatalyst, an aromatic amine, and at least one epoxide to form a reaction mixture, and further contacting the reaction mixture with a gas stream containing carbon dioxide to react the carbon dioxide in the gas stream with the epoxide and the aromatic amine to form a substituted oxazolidinone mixture. The method further includes adding a polar protic solvent to the substituted oxazolidinone mixture, centrifuging, and filtering to produce a recovered Ni-MOF; and further washing the recovered Ni-MOF with an organochloride solvent and drying for at least 5 hours to produce a recycled Ni-MOF.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: December 20, 2022
    Assignee: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS
    Inventors: Aasif Helal, Mohammed Fettouhi, Md. Eyasin Arafat, Mohd Yusuf Khan, Mohammed Ahmed Sanhoob
  • Oxazolidinone for treatment of infections with
    Patent number: 11524002
    Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: December 13, 2022
    Assignees: The Johns Hopkins University, University of St. Thomas
    Inventors: Gyanu Lamichhane, J. Thomas Ippoliti
  • Aldoketo reductase inhibitors and uses thereof
    Patent number: 11518748
    Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: December 6, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Jonathan S. Stamler, William Greenlee, Focco van den Akker
  • Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam
    Patent number: 11518741
    Abstract: The present invention relates to a brivaracetam intermediate, a preparation method therefor, and a preparation method for brivaracetam. The steps of the method for preparing brivaracetam described in the present invention are short and the raw materials are cheap, moreover, the method is simple and highly effective without requiring isomer separation by means of column chromatography or asymmetric synthesis, being suitable for industrial large-scale production. In addition, disclosed by the present invention is a compound as shown in formula (II), which may be used for the synthesis of brivaracetam.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: December 6, 2022
    Assignee: SHANGHAI PUYI CHEMICAL CO., LTD.
    Inventors: Hanrong Yang, Yantao Qi, Tao Li, Bo Wang
  • Agent for inhibiting rise in intraneuronal calcium concentration
    Patent number: 11510914
    Abstract: A method of inhibiting a rise in intraneuronal calcium concentration includes administering an effective amount of a cyclic amine derivative represented by formula (I) or a pharmacologically acceptable salt thereof to a subject in need thereof: wherein A represents formula (IIa), (IIb) or (IIc):
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: November 29, 2022
    Assignee: Toray Industries, Inc.
    Inventors: Kanako Serizawa, Kazumi Nishimura, Tomohiko Suzuki, Tatsuya Nishi
  • Protein translation inhibitors and uses thereof
    Patent number: 11510908
    Abstract: Provided herein are protein translation inhibitors and pharmaceutical compositions thereof that bind to an RNA Recognition motif in heterogeneous ribonucleoprotein A18 to inhibit binding to mRNA transcripts thereby inhibiting protein synthesis. Also provided is a method for treating a cancer by administering a pharmaceutically acceptable amounts of at least one of the protein translation inhibitors.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: November 29, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: France Carrier, Alexander D. MacKerell, David J. Weber, Wenbo Yu
  • Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
    Patent number: 11505533
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 22, 2022
    Assignees: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • Dual inhibitors of TIM-3 and PD-1 pathways
    Patent number: 11497734
    Abstract: The present disclosure relates to 3-substituted 1,2,4-oxadiazole compounds and their derivatives, which are useful as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) inhibitors or as dual inhibitors of TIM-3 and the programmed cell death 1 (PD-1) signaling pathway. The disclosure also relates to treatment of disorders by inhibiting an immunosuppressive signal induced by TIM-3, PD-1, PD-L1, and/or PD-L2.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 15, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan N. Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty S. Naremaddepalli, Nagaraj Gowda
  • Cannabinoid composition and application of the same in preparing medicine for treating neurodegenerative diseases including parkinson's disease and alzheimer's disease
    Patent number: 11497719
    Abstract: Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 15, 2022
    Inventors: Chendong Zou, Hei Tai, Guijiang Wang, Wan Xiao, Sui Huang
  • ?-lactamase inhibitor
    Patent number: 11497731
    Abstract: An object is to provide a compound having ?-lactamase inhibitory activity. The object is achieved by a compound represented by formula (1), typified by a compound in which specific positions of a 5-membered ring having planarity are replaced by sulfamoyl and carboxy groups.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 15, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventors: Yoshichika Arakawa, Jun-ichi Wachino, Kouji Kimura, Wan Chun Jin, Ayato Sato
  • IRAK inhibitors and method for making and using
    Patent number: 11492349
    Abstract: Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: November 8, 2022
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
  • Remdesivir treatment methods
    Patent number: 11491169
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: November 8, 2022
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Compounds useful as kinase inhibitors
    Patent number: 11471441
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: October 18, 2022
    Assignee: Loxo Oncology Inc.
    Inventor: Nicolas Guisot
  • Mcl-1 inhibitors and methods of use thereof
    Patent number: 11472816
    Abstract: Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: October 18, 2022
    Assignee: AstraZeneca AB
    Inventors: Alexander Hird, Matthew Belmonte, Wenzhan Yang, Paul Secrist, Daniel Robbins, Steven Kazmirski, Dedong Wu, Bo Peng, Jeffrey Johannes, Michelle Lamb, Qing Ye, Xiaolan Zheng
  • 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
    Patent number: 11472781
    Abstract: The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: October 18, 2022
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran
  • Methods of inhibiting tumor metastasis
    Patent number: 11471444
    Abstract: Thromboxane A2 receptor antagonists, such as ifetroban, inhibit solid tumor metastasis. The formation of surface and microscopic lung metastases are inhibited. Thromboxane A2 receptor antagonists can inhibit the tumor metastasis process without affecting the growth or development of a primary tumor.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: October 18, 2022
    Assignee: Vanderbilt University
    Inventors: Jill M. Pulley, Robert R. Lavieri
  • Process for preparing Alectinib or a pharmaceutically acceptable salt thereof
    Patent number: 11465999
    Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: October 11, 2022
    Assignee: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Vinod Singh Tomar, Abul Azim, Nitin Gupta, Saswata Lahiri, Walter Cabri